Clinical Trial Update: Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating intravenous imipenem/cilastatin/XNW4107 vs meropenem in hospitalized adults with complicated urinary tract infection including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection
• Pyelonephritis

Drugs mentioned

• Imipenem/Cilastatin-XNW4107
• Meropenem (Meropenem)

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Complicated Urinary Tract Infection Including Acute Pyelonephritis | Phase 3 | Status: UNKNOWN